What Is the ACMD and What Did It Say About Medical Cannabis?

If you’re wondering how medical cannabis fits into UK healthcare, the Advisory Council on the Misuse of Drugs (ACMD) has played a crucial role. This independent UK drug policy advisory body has shaped the evolving legal individual funding request nhs and medical landscape for cannabis-based medicines. In this article, we’ll explain who the ACMD is, what its November 2020 cannabis review concluded, and how it relates to NHS funding, legal prescribing, and access challenges for patients.

Who Is the ACMD?

The Advisory Council on the Misuse of Drugs (ACMD) is a UK government-appointed expert panel that provides scientific and medical advice on drug classification, misuse, and public health impact. Established in 1971, its role is to help Ministers make evidence-based decisions on drug scheduling and policy, considering risks to individuals and wider society.

Think of the ACMD as the government’s go-to independent panel for answering “How dangerous is this substance?” and “Should we change how the law treats it?” They combine insights from experts in medicine, pharmacology, social science, law enforcement, and recovery services.

The 2018 Rescheduling of Cannabis-Based Products for Medicinal Use

Before 2018, cannabis-based products were largely off-limits to doctors except in rare research scenarios. The government classified all cannabis under Schedule 1 of the Misuse of Drugs Regulations 2001, meaning it was considered to have no medicinal value and was tightly controlled.

However, after growing pressure from patients, clinicians, and expert panels including the ACMD, the UK government made a significant change.

November 2018: Cannabis-based products for medicinal use were reclassified as Schedule 2 drugs.
This meant authorised doctors could legally prescribe them when clinically appropriate—especially specialist consultants.
The rescheduling recognised legitimate medical uses, allowing access under strict regulation.

In patient terms: no longer was cannabis-based medicine completely illegal to prescribe—it became possible but still tightly controlled and considered a specialist treatment.

What Changed with This Rescheduling?

Legality versus funding: Legal prescribing became possible, but NHS funding was (and still is) very limited.
Specialist-only prescribing rule: Only consultants registered on the Specialist Register could initiate treatment with cannabis-based products.
Unlicensed medicine caveat: Many prescribed cannabis-based products remain “unlicensed,” meaning they have not been granted full regulatory approval by the MHRA, the UK’s medicines regulator.

The November 2020 ACMD Cannabis Review: What Did It Say?

In November 2020, the ACMD published a major review specifically focusing on cannabis and its derivatives used for medical purposes. The full document is a comprehensive analysis of scientific evidence, prescribing patterns, and policy implications.

Key Conclusions of the November 2020 ACMD Review

Evidence supports some medical uses: Certain cannabis-based products have demonstrated benefit for specific conditions such as treatment-resistant epilepsy and spasticity in multiple sclerosis, though the evidence base is still developing.
Risks and harms: Cannabis products have side effects and vary in strength and composition, so regulated prescribing with specialist oversight remains crucial.
Specialist prescribing remains appropriate: Due to complexities around dosing, risks, and individual variation, the ACMD supported maintaining restrictions to specialist consultants only initiating therapy.
NHS caution is warranted: Given patchy evidence and high cost implications, the NHS should cautiously evaluate cost-effectiveness and clinical benefit. The ACMD recognised that NHS funding decisions are separate from legal prescribing but flagged that funding restrictions limit patient access in practice.
Unlicensed cannabis-based medicines: These are widely used but present regulatory and safety challenges. The ACMD suggested continued oversight and data collection to inform future policy.

Summarising in patient-friendly language: the ACMD said “Yes, some medical cannabis products help certain patients, but doctors must be careful, and the NHS can’t just fund it for everyone yet because we need more proof and to keep people safe.”

Understanding Legal Prescribing Versus NHS Funding

The difference between legal prescribing and NHS funding is often confused. The 2018 rescheduling and ACMD's guidance mean doctors can legally prescribe cannabis-based medicines where clinically appropriate. However, just because it’s legal doesn’t mean the NHS will pay for it.

Legal Prescribing: Post-2018, cannabis-based products for medicinal use are Schedule 2 controlled drugs. Specialist consultants can prescribe them, which is lawful and regulated.
NHS Funding: NHS England has issued Clinical Commissioning Policies restricting routine funding to specific indications (e.g., some types of epilepsy or spasticity). Many patients pay privately or seek out private clinics to get prescriptions outside NHS funding criteria.

For a comprehensive comparison of private clinic services, prices, and patient experiences, medicalcannabis.co.uk offers a useful directory and comparison platform. To understand the broader context of legal prescribing and funding, releaf.co.uk provides patient-friendly explainer content.

Specialist-Only Prescribing Rules: Why Are They Important?

The UK law and ACMD recommendations restrict prescribing of cannabis-based products to specialist doctors, often consultants listed on the GMC Specialist Register relevant to the condition being treated.

Why this specialist-only rule?

Cannabis medicines have complex pharmacology and potential side effects that require specialist knowledge to manage safely.
Specialists can better evaluate whether the benefits outweigh the risks based on evidence and clinical guidelines.
They are responsible for detailed patient assessment, monitoring, and recording outcomes, crucial for accumulating real-world evidence.

For patients, this means your GP cannot usually initiate or prescribe cannabis-based medicines — you need a specialist referral. The ACMD supported continuing this cautious approach in 2020.

Unlicensed Cannabis-Based Medicines and NHS Caution

Unlike licensed medicines, which have full approval after clinical trial evidence, many currently prescribed cannabis-based products are “unlicensed”. This creates caution on several fronts:

Regulatory uncertainty: Unlicensed medicines have not gone through the full MHRA approval process.
Variable quality and formulation: Standardisation of potency and purity can vary, affecting efficacy and safety.
NHS funding risk: NHS England tends to restrict funding to licensed products or those with robust clinical guidelines, making access challenging when only unlicensed products are available.

The ACMD recognised these challenges and urged data collection, patient monitoring, and ongoing research to inform future policy decisions.

Summing Up: The ACMD’s Role in Shaping UK Medical Cannabis Policy

Aspect 2018 Rescheduling November 2020 ACMD Review Practical Impact Legal Status Moved cannabis-based products for medicinal use from Schedule 1 to Schedule 2 Supported maintaining Schedule 2 status with specialist-only prescribing Doctors can legally prescribe medical cannabis under strict regulation Prescribing Restrictions Only specialist consultants can initiate prescriptions Recommended continued specialist-only prescribing due to complexity and risk Patients require referral to specialists; GPs cannot prescribe initially NHS Funding Rescheduling did not guarantee NHS funding Advised NHS caution and cost-benefit evaluation before widespread funding Many patients pay privately; NHS access is limited and condition-specific Unlicensed Medicines Many cannabis-based medicines prescribed remain unlicensed Recommended oversight, data gathering, and further research on unlicensed products Ongoing safety and efficacy concerns; funding and prescribing remain cautious

What Does This Mean for Patients?

If you’re considering medical cannabis, the ACMD’s review and UK drug policy mean:

You can access cannabis-based medicines legally, but only through specialist doctors.
The NHS currently funds treatment only for specific conditions; otherwise, you may need to pay privately.
Many prescribed cannabis medicines are unlicensed, so ask your specialist about product quality and safety.
Tools like medicalcannabis.co.uk help you find clinics and understand options.
Resources at releaf.co.uk explain cannabis medicines simply and clearly.

Remember, legal access is not the same as easy access, and “studies show” is never enough without knowing precisely which ones — the ACMD’s evidence-based approach tries to cut through the hype to protect patients and public health.

Price Considerations

No specific prices were stated in the sources reviewed here. Medical cannabis costs can vary widely depending on the product, clinic, and treatment regimen. If you come across specific price information in future sources, always check carefully and quote prices exactly with attribution.

Many NHS-unfunded patients report private clinic fees running into hundreds or thousands of pounds per year, including consultations, prescriptions, and product costs.